Center for Inflammation, Immunity & Infection, Georgia State University Institute for Biomedical Sciences, Atlanta, GA, United States.
School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, United States.
Front Immunol. 2018 Jul 30;9:1705. doi: 10.3389/fimmu.2018.01705. eCollection 2018.
Skin vaccination using biodegradable microneedle patch (MNP) technology in vaccine delivery is a promising strategy showing significant advantages over conventional flu shots. In this study, we developed an MNP encapsulating a 4M2e-tFliC fusion protein and two types of whole inactivated influenza virus vaccines (H1N1 and H3N2) as a universal vaccine candidate. We demonstrated that mice receiving this tri-component influenza vaccine MNP acquired improved IgG1 antibody responses with more balanced IgG1/IgG2a antibody responses and enhanced cellular immune responses, including increased populations of IL-4 and IFN-γ producing cells and higher frequencies of antigen-specific plasma cells compared with intramuscular injection. In addition, stronger germinal center reactions, increased numbers of Langerin-positive migratory dendritic cells, and increased cytokine secretion were observed in the skin-draining lymph nodes after immunization with the tri-component influenza MNP vaccine. The MNP-immunized group also possessed enhanced protection against a heterologous reassortant A/Shanghai/2013 H7N9 (rSH) influenza virus infection. Furthermore, the sera collected from 4M2e-tFliC MNP-immunized mice were demonstrated to have antiviral efficacy against reassortant A/Vietnam/1203/2004 H5N1 (rVet) and A/Shanghai/2013 H7N9 (rSH) virus challenges. The immunological advantages of skin vaccination with this tri-component MNP vaccine could offer a promising approach to develop an easily applicable and broadly protective universal influenza vaccine.
利用可生物降解的微针贴片(MNP)技术进行皮肤接种在疫苗传递方面是一种很有前途的策略,与传统流感疫苗相比具有显著优势。在这项研究中,我们开发了一种包封 4M2e-tFliC 融合蛋白和两种全灭活流感病毒疫苗(H1N1 和 H3N2)的 MNP,作为一种通用疫苗候选物。我们证明,接受这种三组分流感疫苗 MNP 的小鼠获得了改善的 IgG1 抗体反应,具有更平衡的 IgG1/IgG2a 抗体反应,并增强了细胞免疫反应,包括增加产生 IL-4 和 IFN-γ的细胞和抗原特异性浆细胞的频率与肌肉内注射相比。此外,在三组分流感 MNP 疫苗免疫后,皮肤引流淋巴结中观察到更强的生发中心反应、更多的 Langerin 阳性迁移树突状细胞和更高的细胞因子分泌。MNP 免疫组还对异源重配 A/上海/2013 H7N9(rSH)流感病毒感染具有增强的保护作用。此外,从 4M2e-tFliC MNP 免疫小鼠收集的血清被证明对重配 A/Vietnam/1203/2004 H5N1(rVet)和 A/上海/2013 H7N9(rSH)病毒挑战具有抗病毒功效。这种三组分 MNP 疫苗的皮肤接种的免疫学优势为开发一种易于应用和广泛保护的通用流感疫苗提供了一种很有前途的方法。